DE69232944D1 - Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren - Google Patents

Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Info

Publication number
DE69232944D1
DE69232944D1 DE69232944T DE69232944T DE69232944D1 DE 69232944 D1 DE69232944 D1 DE 69232944D1 DE 69232944 T DE69232944 T DE 69232944T DE 69232944 T DE69232944 T DE 69232944T DE 69232944 D1 DE69232944 D1 DE 69232944D1
Authority
DE
Germany
Prior art keywords
ige
receptor
specific
binding
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69232944T
Other languages
English (en)
Other versions
DE69232944T2 (de
Inventor
M Jardieu
G Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27114350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69232944(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Priority to DE122006000006C priority Critical patent/DE122006000006I2/de
Publication of DE69232944D1 publication Critical patent/DE69232944D1/de
Application granted granted Critical
Publication of DE69232944T2 publication Critical patent/DE69232944T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
DE69232944T 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren Expired - Lifetime DE69232944T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122006000006C DE122006000006I2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74476891A 1991-08-14 1991-08-14
US87949592A 1992-05-07 1992-05-07
PCT/US1992/006860 WO1993004173A1 (en) 1991-08-14 1992-08-14 Immunoglobulin variants for specific fc epsilon receptors

Publications (2)

Publication Number Publication Date
DE69232944D1 true DE69232944D1 (de) 2003-04-10
DE69232944T2 DE69232944T2 (de) 2003-12-24

Family

ID=27114350

Family Applications (3)

Application Number Title Priority Date Filing Date
DE122006000006C Active DE122006000006I2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
DE69233716T Expired - Lifetime DE69233716T2 (de) 1991-08-14 1992-08-14 Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren
DE69232944T Expired - Lifetime DE69232944T2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE122006000006C Active DE122006000006I2 (de) 1991-08-14 1992-08-14 Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
DE69233716T Expired - Lifetime DE69233716T2 (de) 1991-08-14 1992-08-14 Immunglobulinvarianten für spezifische Fc-epsilon Rezeptoren

Country Status (12)

Country Link
EP (2) EP0602126B1 (de)
JP (1) JP3457962B2 (de)
AT (1) ATE233813T1 (de)
AU (2) AU2498192A (de)
CA (1) CA2113813C (de)
DE (3) DE122006000006I2 (de)
DK (2) DK1260521T3 (de)
ES (2) ES2296839T3 (de)
HK (2) HK1050696A1 (de)
LU (1) LU91219I2 (de)
NL (1) NL300220I2 (de)
WO (1) WO1993004173A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
ES2219640T3 (es) * 1992-09-24 2004-12-01 Novartis Ag Anticuerpos monoclonales reformados contra un isotopo de inmunoglobulina.
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5914110A (en) * 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
AP660A (en) * 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US20040197326A1 (en) * 1995-07-27 2004-10-07 Genentech, Inc. Method for treatment of allergic asthma
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
BR9707819A (pt) * 1996-03-01 1999-07-27 Novartis Ag Imunogenos peptidicos
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US7122636B1 (en) 1997-02-21 2006-10-17 Genentech, Inc. Antibody fragment-polymer conjugates and uses of same
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6057127A (en) 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US7393529B2 (en) * 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) * 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
PL350992A1 (en) * 1999-02-25 2003-02-24 Smithkline Beecham Biolog Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
EP1324776B2 (de) 2000-10-12 2018-03-21 Genentech, Inc. Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
WO2003066662A2 (en) 2002-02-05 2003-08-14 Genentech, Inc. Protein purification
US7323553B2 (en) 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
EP3095793B1 (de) 2003-07-28 2020-03-25 Genentech, Inc. Verringerung des protein-a-auslaugens während einer affinitätschromatografie
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US7662926B2 (en) 2004-09-02 2010-02-16 Genentech, Inc. Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI320788B (en) 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
WO2007032804A2 (en) * 2005-06-30 2007-03-22 Clifford Risk Novel uses for anti-ige therapy
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
ES2426158T3 (es) 2007-01-22 2013-10-21 Genentech, Inc. Precipitación con polielectrolito y purificación de anticuerpos
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
JP5687057B2 (ja) 2007-07-09 2015-03-18 ジェネンテック， インコーポレイテッド ポリペプチドの組換え生産中におけるジスルフィド結合還元の防止
PE20090499A1 (es) 2007-08-09 2009-05-18 Boehringer Ingelheim Int Anticuerpos anti-cd37
JP5189098B2 (ja) * 2007-08-23 2013-04-24 三菱化学メディエンス株式会社 非特異反応抑制剤
KR20140015166A (ko) 2007-10-30 2014-02-06 제넨테크, 인크. 양이온 교환 크로마토그래피에 의한 항체 정제
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
ES2749190T3 (es) 2008-08-14 2020-03-19 Genentech Inc Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas indígenas
MX2011002372A (es) 2008-09-10 2011-04-04 Genentech Inc Composiciones y metodos para la prevencion de la degradacion oxidativa de proteinas.
US20110020327A1 (en) 2008-12-16 2011-01-27 Millipore Corporation Purification of proteins
EP2370561B1 (de) 2008-12-16 2019-08-07 EMD Millipore Corporation Rührkesselreaktor und verfahren
SG173812A1 (en) 2009-02-27 2011-09-29 Genentech Inc Methods and compositions for protein labelling
CN102414221A (zh) 2009-03-06 2012-04-11 健泰科生物技术公司 抗体配制剂
KR101822205B1 (ko) 2009-08-11 2018-01-25 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
ES2787234T3 (es) 2009-09-01 2020-10-15 Hoffmann La Roche Purificación de proteínas potenciada a través de una elución de proteína A modificada
MX354867B (es) 2010-03-22 2018-03-23 Genentech Inc Star Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
JP2013525484A (ja) 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
ES2754210T3 (es) 2010-05-17 2020-04-16 Emd Millipore Corp Polímeros sensibles a estímulos para la purificación de biomoléculas
KR20190067277A (ko) 2010-05-28 2019-06-14 제넨테크, 인크. 락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
CA2802756C (en) 2010-06-24 2021-05-04 Genentech, Inc. Compositions and methods for stabilizing protein-containing formulations
EP2603525A1 (de) 2010-08-13 2013-06-19 F.Hoffmann-La Roche Ag Antikörper gegen il-1beta und il-18 zur behandlung von krankheiten
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
WO2013009491A2 (en) 2011-07-08 2013-01-17 Nripen Singh Improved depth filters for disposable biotechnological processes
US9573996B2 (en) 2011-12-16 2017-02-21 Synthon Biopharmaceuticals B.V. Monoclonal antibodies to human proinflammatory cytokines and methods for treating inflammatory diseases
AU2012355356B2 (en) 2011-12-22 2017-10-12 Genentech, Inc. Ion exchange membrane chromatography
SG10202007206WA (en) 2012-03-27 2020-08-28 Genentech Inc Improved harvest operations for recombinant proteins
EP3427721A1 (de) 2012-05-18 2019-01-16 Genentech, Inc. Hochkonzentrierte monoklonale antikörperformulierungen
GB2503883A (en) * 2012-07-09 2014-01-15 King S College London Variant IgE with reduced affinity to CD23
EP2934602B1 (de) 2012-12-19 2019-02-27 Genentech, Inc. Verfahren und zusammensetzungen zur radiohalogen proteinmarkierung
SG11201700097WA (en) 2014-07-09 2017-02-27 Genentech Inc Ph adjustment to improve thaw recovery of cell banks
EP3436610A1 (de) 2016-03-29 2019-02-06 Geltor, Inc. Expression von proteinen in gramnegativen bakterien mit verhältnis von periplasmatischem volumen zu zytoplasmatischem volumen zwischen 0,5:1 und 10:1
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
MX2019007433A (es) 2016-12-22 2019-08-16 Genentech Inc Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
EP3565587A4 (de) * 2017-01-06 2020-12-16 The Regents of The University of California Therapeutische anti-ige-antikörper und verfahren und zusammensetzungen davon
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
US11180541B2 (en) 2017-09-28 2021-11-23 Geltor, Inc. Recombinant collagen and elastin molecules and uses thereof
BR112020006339A2 (pt) 2017-11-07 2020-11-03 Hubit Genomix, Inc. método para prevenção primária de distúrbios alérgicos durante a infância através de imunossupressão específica da classe ige
BR112020025623A2 (pt) 2018-07-03 2021-03-23 Bristol-Myers Squibb Company métodos de produção de proteínas recombinantes
EP3864127A1 (de) 2018-10-10 2021-08-18 Boehringer Ingelheim International GmbH Verfahren zur membrangasübertragung in einer hochdichten bioreaktorkultur
TW202102266A (zh) 2019-04-01 2021-01-16 美商建南德克公司 用於穩定含有蛋白質之配方之組合物及方法
JP2022526434A (ja) 2019-04-12 2022-05-24 ジェルター， インコーポレイテッド 組換えエラスチンおよびその産生
JP2022543781A (ja) 2019-08-01 2022-10-14 ブリストル－マイヤーズ スクイブ カンパニー フェッドバッチ細胞培養におけるタンパク質産生性の改良方法
CN116018352A (zh) 2020-07-10 2023-04-25 上海济煜医药科技有限公司 一种抗IgE的工程化抗体及其应用
KR20230073270A (ko) 2020-09-22 2023-05-25 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 생산 방법
WO2023015234A1 (en) 2021-08-05 2023-02-09 Bristol-Myers Squibb Company Cell culture methods for producing therapeutic proteins
WO2023049687A1 (en) 2021-09-21 2023-03-30 Bristol-Myers Squibb Company Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
JPS63225397A (ja) * 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
US4940782A (en) * 1987-06-08 1990-07-10 G. D. Searle & Co. Monoclonal antibodies against IgE-associated determinants, hybrid cell lines producing these antibodies, and use therefore
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
EP0407392B2 (de) * 1987-12-31 1998-10-28 Tanox Biosystems, Inc. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden

Also Published As

Publication number Publication date
JPH06509944A (ja) 1994-11-10
NL300220I2 (nl) 2006-08-01
CA2113813A1 (en) 1993-03-04
AU7038096A (en) 1997-01-16
EP0602126A1 (de) 1994-06-22
ES2296839T3 (es) 2008-05-01
DE122006000006I2 (de) 2011-06-16
LU91219I2 (fr) 2006-04-03
DE69233716T2 (de) 2008-10-30
ATE233813T1 (de) 2003-03-15
DK1260521T3 (da) 2008-03-25
DE122006000006I1 (de) 2006-04-27
AU706584C (en) 2003-07-10
ES2193136T3 (es) 2003-11-01
HK1014542A1 (en) 1999-09-30
CA2113813C (en) 2005-04-12
EP1260521A3 (de) 2004-01-02
WO1993004173A1 (en) 1993-03-04
DE69233716D1 (de) 2008-01-03
DE69232944T2 (de) 2003-12-24
EP1260521A2 (de) 2002-11-27
DK0602126T3 (da) 2003-06-16
AU706584B2 (en) 1999-06-17
NL300220I1 (nl) 2006-04-03
HK1050696A1 (en) 2003-07-04
JP3457962B2 (ja) 2003-10-20
EP1260521B1 (de) 2007-11-21
AU2498192A (en) 1993-03-16
EP0602126B1 (de) 2003-03-05

Similar Documents

Publication Publication Date Title
DE69232944T2 (de) Veränderte Immunglobuline für spezifische FC-Epsilon Rezeptoren
DE69841170D1 (de) Menschliche Toll-ähliche Rezeptorproteine, zugehörige Reagenzien und Verfahren
ATE321134T1 (de) Menschlicher fc-gamma-rezeptor iii
CA2345024A1 (en) Modified tgf-.beta. superfamily proteins
ATE317852T1 (de) Pollen allergene
ES2187946T3 (es) Uso de interleucina-15.
ATE132197T1 (de) Monoklonale antikörper
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
AU7657387A (en) Apoprotein b-100 specific monoclonal antibodies
DE69315341T2 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DE69230614T2 (de) Protein-s polypeptide und deren verwendungen
DE69232975D1 (de) Protein p100von menschlichem Herpesvirus Typ 6, die korrespondierenden DNS Squenzen, ihre Herstellung und Verwendung
EP0651800A4 (de) Proteine aus granulabasophilen zellen.